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The main goals of this investigation were to prepare a viral DNA vaccine to help stimulate the immune 
system of poultry and to increase the efficiency of this vaccine. To accomplish this work, a strain of H5N1 
circulating in Egypt was confirmed using rapid diagnostic methods and also, reverse transcriptase 
polymerase chain reaction (RT-PCR) to hemagglutinin and neuraminidase genes. The virus was propagated 
in MDCK cell line and the viral genes were extracted and reverse transcribed individually. Individual genes 
were cloned in gene expression vector (PHW2000) and were used as DNA vaccine. The level of maternal 
antibodies was determined by ELISA to appoint the right time to give the vaccine. The chicks were divided 
into eight groups and each group was vaccinated by the couple of DNA NP with one of the other genes. The 
efficiency of coupled DNA vaccine was determined by neutralization assay and compared with the 
inactivated vaccine. The results showed that the vaccine that had NP with NS had adequate protection for 
poultry. 
 





Immunity to conserved viral components can provide 
broad protection against different influenza A strains and 
subtypes. Research immunity has been long studied in 
animals (Lamb and Krug, 2001) and there is evidence 
that it may exist in humans (Fouchier et al., 2005; 
Horimoto and Kawaoka, 2005). Vaccines based on such 
cross-protection would not require knowing the identity of 
the strains that would circulate during the coming season, 
information which is never certain and could avoid hurried 
manufacturing in response to outbreaks. Inactivated 
vaccines given intranasal can induce cross-protection 
(Johnson and Mueller, 2002; Reid et al., 2004), but DNA 
prime-viral boost regimens offer the advantage of 
endogenously expressed antigens that may induce a 
broader range of immune effectors. 
DNA vaccination to conserved influenza nucleoprotien 
NP or NP and matrix proteins (M), has been studied in 
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mismatched challenge viruses has been demonstrated 
(Gamblin et al., 2004; Horimoto and Kawaoka, 2005),  
albeit with relatively low dose challenges. H5N1 viruses 
from the 1997 human outbreak in Hong Kong presented 
a demanding test because of their virulence and rapid 
kinetics of infection (Matrosovich et al., 2000). Limited 
protection was achieved by DNA vaccination with NP + M 
against some lethal H5N1 challenges (Subbarao et al., 
1998). To improve the efficacy of this approach, Epstein 
et al. (2005) explored the ability of a recombinant 
adenovirus (rADV) vector to enhance potency of vacci-
nation to NP, an antigen with >90% protein sequence 
homology among influenza A isolates (Buxton et al., 
2000) and containing dominant target epitopes (Xu et al., 
1999). The ability of the regimen to protect against high 
virus challenge doses and against challenge with 
mismatched highly pathogenic H5N1 strains was tested. 
The DNA prime-rADV boost regimen is more effective 
than vaccination with NP construct, conferring protection 
against doses of challenge virus that were lethal to mice 
vaccinated only with DNA or rADV. In this study, investi-
gation was carried out to find effective system for 
protection against lethal doses of H5N1 by preparing  DNA 




vaccine from mixture of the NP construct with other viral 
gene constructs to find the one that is more effective in 
poultry protection. 
An epidemic of disease occurs when there are more 
cases of that disease than normal, while pandemics are 
worldwide epidemic of a disease. An influenza pandemic 
may occur when a new influenza virus appears against 
which the human population has no immunity. The avian 
influenza viruses AI have devastating impact on poultry 
causing nearly 100% mortality within 48 h of infection 
(Roberts and Lim, 2008). 
Inactivated vaccines are the main stream of influenza 
prophylaxis (Horimoto and Kawaoka, 2006). The first of 
the inactivated vaccine formulation is the whole virion, the 
experimental use of which dates back to 1940s. The 
second is split virion which is derived by disrupting whole 
virus particles with detergents and finally, the subunit 
form, which is prepared by enriching for the viral surface 
glycoproteins HA and neuraminidase (NA) following 
disruption of viral particles, although, arguably more 
immunogenic.  
This system consists of a plasmid that synthesizes the 
six gene segments for the internal proteins (PB2, PB1, 
PA, NP, M and NS) and a second plasmid that 
synthesizes the HA and NA segments. A total of four 
plasmids are used for transfection into Vero cells, 
(Horimoto and Kawaoka, 2006) which results to reassortant 
viruses. This four-plasmid system might therefore, be 
valuable in the future generation of pandemic vaccine 
seed viruses. The HA and NA were derived from a 
human H5N1 virus and the rest of their genes were 
derived from a virus (known as backbone virus) that 
grows well in eggs (Horimoto et al., 2006).  
Previous vaccination with seasonal trivalent, inactivated 
or live attenuated influenza vaccines did not elicit a cross-
reactive antibody response to the novel strains of H1N1 
and H5N1 viruses. The currently licensed seasonal 
influenza vaccines are subtype specific, thus, do not 
induce protective immune responses against newly 
emerged influenza viruses. Up till now, a protective 
vaccine for the H5N1 influenza virus is not available due 
to several problems that include shortening the time from 
vaccine strain selection to vaccination, increasing the 
capacity of production, broadening the vaccine-induced 
immune response, and evaluating the vaccine’s effective-
ness and safety (Monto and Ohmit, 2009). 
DNA vaccines represent a novel and powerful 
alternative to conventional vaccine approaches. Their 
novelty and usefulness stems form the fact that, they are 
noninfectious, nonreplicating, extremely stable and can 
be produced en masse at low cost. Most importantly, 
DNA vaccines against emerging pathogens or bioterrorism 
threats can be quickly constructed based solely upon the 
pathogen’s genetic code (Kim and Jacob, 2009; Donnelly 
et al., 2005). The aims of this study were to develop eight 
DNA constructs of influenza A virus in mammalian 
expression system, immunization of chicken by mixing 





evaluation study for the most effective mixture by 
determination of the immune response. 
 
 




The avian influenza H5N1 (A/chicken/Qalubiya/1/2006(H5N1)), 
(Egyptian strain) was kindly provided by Prof. Dr. Mohamed Ali, 
National Research Centre in Cairo. The obtained virus was 
previously identified as AVI H5N1virus by both RT-PCR and 
nucleotide sequencing.  
The nucleotide sequence of the HA gene was deposited in the 





For H5, the following forward (F) and reverse (R) primers were 
designed based on previously published sequence using the 
Lasergene sequence analysis software (DNASTAR Inc., Madison, 
USA) to amplify partial sequence of a 311 bp segment:       H5-F: 5'-
CCTCCA GARTATGCMTAYAAAATTGTC-3'; H5-R 5'-
TACCAACCGTCTACCATKCCYTG -3’.  
For neuraminidase (N1), the following previously published 
(Wright et al., 1995) F and R primers were used to amplify the 
partial sequence of 615 bp segment:        N1-F:   5’-
TTGCTTGGTCGGCAAGTGC-3’; N1-R:  5’- 
CCAGTCCACCCATTTGGATCC-3’.  
Another set of universal primers (Hoffmann et al., 2001) that was 
recomended for amplification of eight segments for all the influenza 
“A” viruses were used. These primers were: PB2-1F 
tattggtctcagggAGCGAAAGCAGGTC; PB2-2341R   
atatggtctcgtattAGTAGAAACAAGGTCGTTT; PB1-1 F         
tattcgtctcagggAGCGAAAGCAGGCA; PB1-2341R   
atatcgtctcgtattAGTAGAAACAAGGCATTT; PA-1  F         
tattcgtctcagggAGCGAAAGCAGGTAC; PA-2233R     
atatcgtctcgtattAGTAGAAACAAGGTACTT; HA-1 F         
tattcgtctcagggAGCAAAAGCAGGGG; NS-890R       
atatcgtctcgtattAGTAGAAACAAGGGTGTTTT; NP-1  F         
tattcgtctcagggAGCAAAAGCAGGGTA; NP-1565R     
atatcgtctcgtattAGTAGAAACAAGGGTATTTTT; NA-1  F        
tattggtctcagggAGCAAAAGCAGGAGT; NA-1413R    
atatggtctcgtattAGTAGAAACAAGGAGTTTTTT; M-1   F         
tattcgtctcagggAGCGAAAAGCAGGTAG; M-1027R      
atatcgtctcgtattAGTAGAAACAAGGTAGTTTTT; NS-1T F       
tattcgtctcagggAGCGAAAAGCAGGGTG; NS-890R      
atatcgtctcgtattAGTAGAAACAAGGGTGTTTT; Uni 12 primer 5’-
AGCAAA AGCAGG-3’  
 
 




pHW2000 vector was kindly provided by Prof. Dr. Mohamed Ali, of 
the National Research Centre in Cairo, from Dr. Richard Webby, 
St.Jude Children’s Research Hospital and Memphis, USA through 
Materials Transfer Agreement (MTA) (Figure 1).  
 
 
RT-PCR: Virus RNA extraction 
 
Viral RNA extraction was accomplished using the viral RNA 
extraction reagent kit and the manufacturing instructions as 
procedures.   










Reverse transcription of extracted RNA 
 
Reverse transcription of the extracted RNA was performed for 
synthesis of cDNA, using the method of Hoffmann et al. (2000). 
Polymerase chain reaction (PCR) of both H5 and N1 partial 
sequences and visualization of RT-PCR product was carried out 
according to the method of Wright et al. (1995).  
 
 
Production of polyclonal antibodies against the killed H5N1: 
Egyptian strain 
 
Madin Darby canine kidney cell (MDCK) tissue culture was grown to 
confluence the complete growth media (DMEM) in 75 cm
2
 culture 
flasks as route protocol stander work. 
 
 
Propagation of H5N1: Egyptian isolate in MDCK 
 
Avian influenza H5N1 virus (A/chicken/Qalubiya/1/2006(H5N1)) 
was propagated in MDCK as route protocol stander work.   
 
 
H5N1 virus titration 
 
Plaque forming unit (PFU) assay was used for H5N1 virus titration, 
applying the method of Rashad and Ali (2006).  
 
 
Preparation of killed H5N1: Egyptian isolate 
 
HPAI-H5N1virus was inactivated by 0.1% formaldehyde (1 µl/ml), 
and then was treated with sodium thiosulfate solution (1 mg/ml) to 
remove the residual formaldehyde. The killed virus was mixed with 
four volumes of Negilla sativa oil that was previously reported to 
induce both cellular and humoral immune responses upon being 
used as an adjuvant (Salem, 2005). 
 
 
Immunization of chicks for production of polyclonal antibodies 
 
Three groups of three days old chicks (each of five) were used for 
the production of polyclonal antibodies. The first group was 
immunized with intramuscularly injection with 200 µl solution 
containing 106 PFU killed virus. The second group was immunized 
with lysate of uninfected MDCK host cells and the third group was a 
control left unimmunized. Immunized chickens received a booster 
dose of the killed virus three weeks after the first immunization. 
Serum samples were collected from the three groups before 
immunization and then weekly post-immunization. 
 
 
Preparation of construct DNA vaccine 
 
RT-PCR amplification of each viral gene using full length 
primers 
 
Each viral gene of H5N1 was amplified by RT-PCR using full length 
primers as applied by Hoffmann et al. (2000).  
 
 
Purification of the PCR products 
 
Five volumes of buffer PB was added to one volume of the PCR 
sample and was mixed by the QIAquick spin column.  
 
 
Cloning of amplified viral segments for preparation of DNA 
constructs  
 
Digestion of the amplified genes and pHW2000 was with 
BsmB1endonuclease and the amplified genes and pHW2000 were 
digested with BsmB1endonuclease using the method of Hoffmann 
et al. (2002). 
 
 
Ligation of each gene in plasmid terminal with T4 ligase 
 
The ligation reaction was done using the T4 DNA ligase kit 
(Promega). Briefly the vector was centrifuged and DNA tubes were 
inserted to collect the contents at the bottom of the tube. The 
reaction mixture was prepared with 8 µl of the digested vector 
(BsmBI), 2 µl 10X buffer, 8 µl digested PCR of NA (BsaI) and 2 µl 
T4 DNA ligase. The mixture was incubated at 4°C overnight. 
 
 
Transformation of each construct in E. coli (Top 10 competent 
cells) 
 
To transform each construct in E. coli, 50 µl of the  TOP10   compe- 




tent bacterial vial and 5 µl ligation mixtures were added according 
to the routine stander method protocol. 
 
 
Selection of the transformed bacterial colony and extracted 
plasmid by miniprep 
 
This was done according to the manufacturer’s instructions 
(plasmid minipreparation kit, promega). 
 
 
Confirmation of the constructed DNA 
 
PCR for each constructed DNA was performed according to routine 
stander method protocol. 
 
 
Large-scale preparation of plasmid DNA  
 
The method was done according to the manufacturer’s instructions 
(plasmid maxi preparation kit; QIAGEN, Hilden, Germany). 
 
 
Determination of maternal antibodies against H5N1 virus 
 
Maternal IgG antibodies against H5N1 virus were determined by 
ELISA according to the method of Bahgat et al. (2006).  
 
 
Vaccination of chicks 
 
A suspension of the NP construct DNA with each of the seven 
constructed DNA was prepared individually according to routine 
stander method protocol. 
 
 
Detection of immunoglobulin G (IgG) against constructed DNA 
 
Antibodies produced against each DNA vaccine constructs were 
detected by ELISA according to the method of Bahgat et al. (2006).  
 
 
Neutralization assay for antibodies titration 
 
Procedure of virus titration 
 
Microtitre plates were seeded with MDCK cells. Monolayer of 
MDCK cell in the T-75 flask was gently rinsed with 5 ml trypsin 
EDTA. Trypsin-EDTA (5 ml) was added to cover the cell monolayer. 
The flask was laid flat and incubated at 37°C in 5% CO2 until the 
monolayer detached (approximately 10 min). MDCK medium (5 ml) 
was added to each flask and cell was removed and transferred to 
centrifuge tube.  
The cells were washed with PBS (5 min at 12,000 rpm). Cells 
were resuspended in D-MEM cell growth medium and counted with 
a hemocytometer. Cells number was adjusted to 1.5x105 cell/ml 
with D-MEM growth medium. Cells suspensions (100 µl/well) were 
added into microtiter plate. Plate was incubated overnight at 37°C, 
at 5% CO2 for 18 to 22 h. Plate was used when cell just reached 




Preparation of virus dilutions 
 
Virus was diluted 1/10 in the virus growth media VGM (working 







Virus titration was done according to routine stander method 
protocol. The TCID50 was calculated by the Read-Meunch method. 
 
 
Preparation dilutions of test sera 
 
Collected sera were diluted in DMEM media. A volume of 12 l from 
each serum was added to 108 µl of DMEM media free FBS and 
was decontaminated by antibiotic mixture in 0.5 ml tubes. Wells in 
the microtiter plate were coated with 60 l DMEM media free FBS 
and were decontaminated by antibiotic mixture except the first row 
(uncoated). Wells in the first row received 60 l of the serum 
dilution. Equal volumes (60 µl) of DMEM media free FBS and 
decontaminated by antibiotic mixture were added to each well of 
the first row. Twofold serial dilution was prepared by transferring 60 
l from row to row (A, B, C to H) and 60 l was discarded from the 
last row (row H). 
The highest dilution of each serum completely protecting the cell 
sheet from CPE in at least two wells of four was taken to be the 





Propagation and titration of the H5N1 Egyptian 
isolate 
 
The virus isolate was propagated in MDCK cells with 
daily microscopic examination. Due to virus propagation 
after 2 days of post infection, CPE appeared on the 
infected cells as demonstrated by marked morphological 
changes including rounding, clumping, darkness and 
destruction in the cell monolayer and this effect increased 
dramatically by day 4 (Figure 2).  
Harvested virus from MDCK-infected cells at day 4 was 
titrated by plaque infectivity assay. Results showed that 
the virus titer was approximately 10
6
 PFU/ml (Table 1). 
 
 
Amplification of H5N1 Full length of eight segments 
 
Amplification of the eight viral segments was carried out 
using RT-PCR and specific primers for each segment. 
The results clearly demonstrated that amplification of 
2341, 2341, 2233, 1565, 1027, 890, 1778 and 1413 bp 
fragments, respectively, corresponded with the expected 
molecular weights (band size) of PB2, PB1, PA, NP, M, 
NS, HA and NA genes (Figure 3). 
 
 
cDNA cloning of extracted RNA in expression vector 
 
The RT-PCR products of each segment were purified 
with Qiagen PCR purification reagent and individually 
cloned in pHW2000 mammalian expression vector. The 
cloned pHW2000 of each segment was transformed in 
top 10 competent bacterial cells for propagation. The 
constructed plasmid was extracted  from  the  propagated  




Table 1. Plaque titration of HPAIV H5N1. 
 
Dilution Replica 1 Replica 2 Replica 3 Average number of plaque PFU/ml 
10-1 Unc Unc Unc Unc Und 
10-2 Unc Unc Unc Unc  
10-3 110 95 105 103 103x10x103=1x106 
10-4 15 7 12 25 9x10x104=9x105 
10-5 0 0 0 0 0 
 
Unc, Uncountable; Und, undetermined.  Titration = 1×106 + 9×105 = 22×105 = 2×106 pfu/ml.           
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Figure 2. MDCK cells infected with H5N1 HPAIV. (A), Control uninfectedcells; (B and C), infected cells with 

















Figure 3. RT-PCR amplification products of the eight virus full length segments. M is 1Kb molecular 
weight marker. 




PB2         PB1         PA         HA          NP          NA           M           NS 
 
 
Figure 4. Electrophoretic analysis of the constructed plasmid with individual 










transformed bacteria and run in gel-electrophoresis 
(Figure 4).  
 
 
Confirmation of cloning 
 
Confirmation of the constructed DNA was achieved by 
amplifying each constructed plasmid containing segment 
using PCR and specific primers for each segment. The 
results clearly demonstrated that, amplification of 2341, 
2341, 2233, 1565, 1027, 890 and 1778 bp, respectively 
and 1413 fragments, corresponded to the expected 
molecular weights (band size) of PB2, PB1, PA, NP, M, 
NS, HA and NA gene. 
 
 
Determination of IgG maternal antibodies of the 
chicks groups against H5N1 isolate 
 
The success of vaccination program of poultry depends 
on the absence of maternal antibodies against avian 
influenza H5 in the vaccinated chicks. So, the 
recommended age for the prime dose was one day old. 
Because all chicks came from vaccinated mothers, the 
maternal antibodies interfered with vaccine efficiency. 
Accordingly, the maternal antibodies against H5N1 virus 
was monitored weekly using ELISA to determine the 
maximum drop in maternal antibodies. The optical 
density (O.D) of the IgG maternal antibody against H5N1 
in one week old chicks was 0.84. After the second week, 
the value of O.D. dropped to 0.54. The maximum drop in 
IgG maternal antibodies was observed at the third week 
(0.42) (Figure 5).  
 
 
Detection of IgG antibodies against each couple of 
construct DNA vaccine 
 
Antibodies produced against each DNA vaccine 
constructs and inactivated vaccine were detected by 
ELISA (Figure 6). Although, each serum was diluted 1:1, 
the results of ELISA according to the OD  value  indicated  






Figure 6. Detection of antibodies against each couples of DNA constructs and inactivated 




Table 2.   Detection of IgG antibodies against 
each couple of construct DNA vaccine and 
inactivated vaccine. 
 
Type of vaccine OD 












high variations in the concentration of antibodies 
produced against each couple of DNA construct. The 
highest OD was obtained with inactivated vaccine of 
H5N1 (1.7). The lowest OD was obtained with NP/NP, 
where the highest OD was obtained with DNA construct 
vaccine was with NP/NS (1.2). Table 2 indicates all the 




Titration of IgG antibody against each couples of 
DNA constructs and inactivated vaccine by 
neutralization assay 
 
The neutralizing titer of the H5N1 genome segment 
couples was determined by neutralization assay. The 
titers were compared with the prepared H5N1 oil emul-
sion inactivated vaccine. Results clearly demonstrated 
that, titers of 2 , 8, 8, 2, 16, 2, 2, 2, 64 and 128, respec-
tively corresponded with NP/NP,  NP/PB1, NP/PB2, 
NP/PA, NP/HA, NP/NA, NP/M, NP/NS and H5N1 
vaccine. The results revealed that, the maximum 
neutralizing efficiency was obtained by the NP/NS couple 





The 1997 outbreak of H5N1 avian influenza in humans in 
Hong Kong and frequent subsequent outbreaks in China 
and Eastern Europe resulted to great concern in the 
world health community (Subbarao et al., 1998). This is 
because, the outbreaks was caused by highly pathogenic 
strains of an influenza subtype to which humans lack 
immunity and hence, poses the potential to cause an 
influenza pandemic, as seen in 1918. Considering the 
molecular basis for the virulence of H5N1 viruses (Hatta 
et al., 2001), the most promising method of controlling a 
pandemic is the use of antiviral drugs (Laver and 
Garman, 2001). However, these drugs partially reduce 
the symptoms and duration of the disease and drug 
resistance has been found in multiple isolates 
(Schunemann et al., 2007). Genomic and antigenic 
analyses  of  H5N1  viruses  isolated   since   2004   have  

































*No.  infected 
/ total 
1:1 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 
1:2 2/4 0/4 0/4 2/4 0/4 2/4 2/4 0/4 0/4 
1:4 3/4 0/4 0/4 3/4 1/4 3/4 3/4 0/4 0/4 
1:8 4/4 2/4 2/4 4/4 0/4 34 3/4 0/4 0/4 
1:16 4/4 3/4 3/4 4/4 2/4 4/4 4/4 1/4 0/4 
1:32 4/4 4/4 4/4 4/4 3/4 4/4 4/4 0/4 1/4 
1:64 4/4 4/4 4/4 4/4 4/4 4/4 4/4 2/4 0/4 
1:128 4/4 4/4 4/4 4/4 4/4 4/4 4/4 4/4 2/4 
 











revealed at least two distinct sub-lineages with different 
geographic distributions, designated clades 1 and 2 
(Webster and Govorkova, 2006). This raises the concern 
that it is not possible to predict which strain may emerge 
in a future pandemic; therefore, a vaccine generated from 
a single selected strain may not be able to protect against 
a diverse set of viruses. In addition, there are several 
inherent difficulties associated with H5N1 vaccines 
(Stephenson et al., 2006; Subbarao and Luke, 2007). H5 
viruses are highly pathogenic, yet H5-HA is poorly 
immunogenic for unknown reasons. Little is known about 
the antigenic sites on avian HAs and immune correlation 
of protection from avian influenza infections. In 
comparison with human-adapted influenza viruses, the 
yield of candidate vaccines of H5N1 in embryonic chicken 
eggs was reduced and limited. The manufacturing 
capacity represents an additional obstacle in the 
development of H5N1 vaccines. Thus, the major focus in 
H5N1 vaccine development is on testing vaccine 
candidates for priming, cross-reactivity and cross-
protection against infection with viruses from different 
clades and subclades. 
Studies have explored the possibility of developing 
DNA vaccines against H5N1 influenza viruses (Epstein et 
al., 2005; Laddy et al., 2007). As in human influenza 
viruses, the protective ability of HA-based DNA vaccines 
of H5N1 virus is limited to homologous strains of virus. 
Kodihalli and colleagues showed that, a DNA vaccine 
encoding HA from the index human influenza isolate 
A/HongKong/156/97, provided immunity against 
homologous H5N1 infection of mice (Kodihalli et al., 
1999). 
However, a DNA vaccine encoding the HA from A/ 
Ty/Ir/1/83 (H5N8), which differs from A/HK/156/97 
(H5N1) by 12% in HA1, prevented death but not H5N1 
infection (Kodihalli et al., 1999). The possibility of 
protection conferred by NA-based DNA vaccines has also 
been explored (Sandbulte et al., 2007). Based on the 
idea that the NA of H5N1 viruses (avN1) and endemic 





serotype, Sandbulte’s group tested whether an immune 
response to huN1 could mediate cross-protection against 
H5N1 influenza virus infection (Sandbulte et al., 2007).  
A DNA vaccine encoding huN1 from A/PR/8/34 (H1N1) 
partially protected mice from lethal challenge with H5N1 
virus or recombinant PR8-avN1. These findings suggest 
that, a portion of the human population could have some 
degree of resistance to H5N1 influenza (Sandbulte et al., 
2007). More promising results regarding cross-protection 
are found in studies where internal protein-based DNA 
vaccines were applied. Epstein and colleagues showed 
that, DNA vaccination encoding the PR8 (H1N1)-NP and 
M1 proteins, reduced replication of A/HongKong/486/97, 
a non-lethal H5N1 strain in mice and completely 
protected and minimized morbidity upon lethal challenge 
with more virulent A/HongKong/156/97 (Epstein et al., 
2002). Upon challenge with a highly virulent strain of 
HK/483, half of the vaccinated mice survived (Epstein et 
al., 2002). The strategy of combined DNA vaccination 
against H5N1 virus was also shown to be effective 
against other viruses, such that H5- and H7-encoding 
DNA vaccines, protected chickens against lethal infection 
by both A/Ck/Vic/1/85 (H7N7) and A/Ty/Ir/1/83 (H5N8) 
(Kodihalli et al., 2000).  
In this study, the effect of maternal antibodies which 
could decrease or increased the efficiency of the 
construct DNA vaccine or H5N1 vaccine where countered 
by vaccinating the chick till the dropping of maternal 
antibodies. At this moment, the chicken will be ready for 
vaccination with oil emulsion inactivated vaccine. The use 
of DNA vaccination may resolve this problem but the 
selective gene segment is needed to try different couples 
of segments and that was what was performed in this 
study. The NP protein segment was selected to be the 
main DNA for vaccination because it is known that this 
segment is highly conserved. The results revealed that 
the couples of NP and NS gave the highest neutralizing 






Avian influenza viruses are still the most infectious 
agents of the 21st century worldwide. No expected 
changes or mutations can be predicted for these viruses. 
The use of DNA vaccines may be the promising tool for 
virus control and eradication. This is beside the low cost 
for vaccine preparation and use. The main advantage of 
this type of vaccines is that, it may lead to a universal 
vaccine for influenza A infection. In this study, production 
of antibodies against H5N1 virus by chick immune 
system could be achieved using construct DNA vaccine. 
As it was shown in the results, the couple construct DNA 
vaccine of NP/NS gave the highest antibodies titer (1:64) 
compared with other couple construct DNA vaccines and 
it was almost the next titer of H5N1 inactivated vaccine 
(1:128).  The  two  folds   difference   would   not   be   an  




obstacle of using this type of vaccine instead of 
inactivated vaccine in the comparison of the advantages 
and disadvantages of the application of these two types 
of vaccines. 
Surveillance for influenza viruses is an urgent need for 
developing and developed countries. The developing 
countries must obtain the technology of vaccine 
preparation to avoid what happened in swine influenza 
pandemic of 2009. Researches must continue in the field 
of virus characterization and vaccine evaluation. This 
study could be considered as pilot study for the 
production of a DNA vaccine against H5N1 virus. As long 
as the production of antibodies was enhanced in this 
study by using DNA vaccine, further studies for vaccine 
evaluation are required. Trials and investigations 
concerning the efficacy of this vaccine against the 
infection with other strains and subtypes of influenza 
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